LONDON, April 14, 2014 /PRNewswire/ --
On Friday, April 11, 2014, the
NASDAQ Composite ended at 3,999.73, down 1.34%, the Dow Jones
Industrial Average declined 0.89%, to finish the day at 16,026.75,
and the S&P 500 closed at 1,815.69, down 0.95%. The losses were
broad based as all the sectors ended the session in negative. The
S&P 500 Health Care Sector Index ended the day at 644.74, down
1.07%, and the same has fallen by 2.36% in the previous three
months. Investor-Edge has initiated coverage on the following
equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Medivation
Inc. (NASDAQ: MDVN), Mast Therapeutics Inc. (NYSE MKT: MSTX) and
Athersys Inc. (NASDAQ: ATHX). Free technical research on ACHN,
MDVN, MSTX and ATHX can be downloaded upon signing up at:
http://www.investor-edge.com/1184-register
Achillion Pharmaceuticals Inc.'s stock recorded a trading volume of
1.95 million shares, as compared with its three months average
volume of 1.90 million shares. The stock ended the day at
$2.88, down 4.00%, after trading
between $2.84 and $3.10. Achillion
Pharmaceuticals Inc.'s shares have plummeted 5.57% in the previous
three trading sessions, 10.56% in the last one month and 13.23% on
YTD basis. The company's stock is trading below its 50-day and
200-day moving averages. Achillion Pharmaceuticals Inc.'s 200-day
moving average of $4.41 is above its
50-day moving average of $3.36.
Further, the stock has a Relative Strength Index (RSI) of 36.60.
Sign up today to read free research on ACHN at:
http://www.investor-edge.com/1184-ACHN-.pdf
On Friday, Medivation Inc. finished the session 5.56% lower at
$55.08. A total of 1.63 million
shares were traded, which is above its three months average volume
of 1.53 million shares. The stock fluctuated between $55.00 and $59.24 during the session. Medivation
Inc.'s stocks have plummeted 8.78% in the previous three trading
sessions, 20.70% in the last one month and 13.69% on YTD basis. The
stock is trading below its 50-day and 200-day moving averages of
$71.68 and $63.35, respectively. Furthermore, the stock has
an RSI of 28.91. Sign up today to read free research on MDVN
at:
http://www.investor-edge.com/1184-MDVN-.pdf
Shares in Mast Therapeutics Inc. fluctuated between $0.55 and $0.62 before ending Friday's session
11.36% lower at $0.55. Mast
Therapeutics Inc.'s stock reported a trading volume of 3.51 million
shares, as compared with its three months average volume of 4.04
million shares. Mast Therapeutics Inc.'s shares have declined
14.46% in the previous three trading sessions, 31.25% in the last
one month, but the same has gained18.95% on YTD basis. The stock is
trading below its 50-day and 200-day moving averages of
$0.77 and $0.56, respectively. Additionally, the stock has
an RSI of 25.95. Sign up today to read free research on MSTX
at:
http://www.investor-edge.com/1184-MSTX-.pdf
On Friday, Athersys Inc.'s stock plummeted 4.98%, to close the day
at $2.86. The stock recorded trading
volume of 0.79 million shares, as compared with its three months
average volume of 1.26 million shares. The stock oscillated between
$2.83 and $2.99 during the trading
session. Athersys Inc.'s shares have declined 4.67% in the previous
three trading sessions, 22.28% in the last one month, while the
same has advanced 14.40% on YTD basis. The stock is trading above
its 200-day moving average. Athersys Inc.'s 50-day moving average
of $3.56 is above its 200-day moving
average of $2.44. Furthermore, the
company's shares have an RSI of 29.51. Sign up today to read free
research on ATHX at:
http://www.investor-edge.com/1184-ATHX-.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge